Atherosclerosis
Volume 206, Issue 2 , Pages 328-334 , October 2009

Thromboangiitis obliterans in the 21st century—A new face of disease

Received 22 September 2008 ,Revised 14 January 2009 ,Accepted 30 January 2009.

References 

  1. Olin JW. Thromboangiitis obliterans (Buerger's disease). N Engl J Med. 2000;343:864–869
  2. Wysokiński W, Kwiatkowska W, Sapian-Raczkowska B, et al. Sustained Classic Spectrum of Thromboangiitis Obliterans. Angiology. 2000;51:141–150
  3. Kobayashi M, Nishikimi N, Komori K. Current pathological and clinical aspects of Buerger's disease in Japan. Ann Vasc Surg. 2006;20:148–156
  4. Laohapensang K, Rerkasem K, Kattipattanapong V. Seasonal variation of Buerger's disease in Northern part of Thailand. Eur J Vasc Endovasc Surg. 2004;28:418–420
  5. Ates A, Yekeler I, Ceviz M, et al. One of the most frequent vascular diseases in northeastern of Turkey: thromboangiitis obliterans or Buerger's disease (experience with 344 cases). Int J Cardiol. 2006;111:147–153
  6. Zannini G, Cotrufo M. Epidemiological, angiographic and clinical aspects of Buerger's disease. J Cardiovasc Surg (Torino). 1973;14:17–20
  7. Lie JT. The rise and fall and resurgence of thromboangiitis obliterans (Buerger's disease). Acta Pathol Jpn. 1989;39:153–158
  8. Yorukoglu Y, Ilgit E, Zengin M, et al. Thromboangiitis obliterans (Buerger's disease) in women (a reevaluation). Angiology. 1993;44:527–532
  9. Sasaki S, Sakuma M, Kunihara T, Yasuda K. Current trends in thromboangiitis obliterans (Buerger's disease) in women. Am J Surg. 1999;177:316–320
  10. Rahman M, Chowdhury AS, Fukui T, Hira K, Shimbo T. Association of thromboangiitis obliterans with cigarette and bidi smoking in Bangladesh: a case-control study. Int J Epidemiol. 2000;29:266–270
  11. Disdier P, Granel B, Serratrice J, et al. Cannabis arteritis revisited—ten new case reports. Angiology. 2001;52:1–5
  12. McLoughlin GA, Helsby CR, Evans CC, Chapman DM. Association of HLA-A9 and HLA-B5 with Buerger's disease. Br Med J. 1976;2:1165–1166
  13. Jaini R, Mandal S, Khazanchi RK, Mehra NK. Immunogenetic analysis of Buerger's disease in India. Int J Cardiol. 1998;66(Suppl. 1):S283–S285
  14. de Moerloose P, Jeannet M, Mirimanoff P, Bouvier CA. Evidence for an HLA-linked resistance gene in Buerger's disease. Tissue Antigens. 1979;14:169–173
  15. Mills JL. Buerger's disease in the 21st century: diagnosis, clinical features, and therapy. Semin Vasc Surg. 2003;16:179–189
  16. Bollinger A, Hollmann B, Schneider E, Fontana A. [Thrombangiitis obliterans: diagnosis and therapy in light of new immunological findings]. Schweiz Med Wochenschr. 1979;109:537–543
  17. Kroger K, Kreuzfelder E, Moser C, et al. Thrombangitis obliterans: leucocyte subpopulations and circulating immune complexes. Vasa. 2001;30:189–194
  18. Kim EJ, Cho BS, Lee TS, Kim SJ, Seo JW. Morphologic change of the internal elastic lamina in Buerger's disease. J Korean Med Sci. 2000;15:44–48
  19. Kobayashi M, Ito M, Nakagawa A, Nishikimi N, Nimura Y. Immunohistochemical analysis of arterial wall cellular infiltration in Buerger's disease (endarteritis obliterans). J Vasc Surg. 1999;29:451–458
  20. Kurata A, Machinami R, Schulz A, Fukayama M, Franke FE. Different immunophenotypes in Buerger's disease. Pathol Int. 2003;53:608–615
  21. Halacheva K, Gulubova MV, Manolova I, Petkov D. Expression of ICAM-1, VCAM-1, E-selectin and TNF-alpha on the endothelium of femoral and iliac arteries in thromboangiitis obliterans. Acta Histochem. 2002;104:177–184
  22. Lee T, Seo JW, Sumpio BE, Kim SJ. Immunobiologic analysis of arterial tissue in Buerger's disease. Eur J Vasc Endovasc Surg. 2003;25:451–457
  23. Czarnacki M, Gacka M, Adamiec R. The role of endothelin-1 in pathogenesis of Buerger's disease (a preliminary report). Przegl Lek. 2004;61:1346–1350
  24. Slavov ES, Stanilova SA, Petkov DP, Dobreva ZG. Cytokine production in thromboangiitis obliterans patients: new evidence for an immune-mediated inflammatory disorder. Clin Exp Rheumatol. 2005;23:219–226
  25. Makita S, Nakamura M, Murakami H, et al. Impaired endothelium-dependent vasorelaxation in peripheral vasculature of patients with thromboangiitis obliterans (Buerger's disease). Circulation. 1996;94(9 Suppl):II211–II215
  26. Schellong SM, Rautmann A, Gross WL, Alexander K. No ANCA in thromboangiitis obliterans (Burger's disease). Adv Exp Med Biol. 1993;336:327–330
  27. Halacheva KS, Manolova IM, Petkov DP, Andreev AP. Study of anti-neutrophil cytoplasmic antibodies in patients with thromboangiitis obliterans (Buerger's disease). Scand J Immunol. 1998;48:544–550
  28. Eichhorn J, Sima D, Lindschau C, et al. Antiendothelial cell antibodies in thromboangiitis obliterans. Am J Med Sci. 1998;315:17–23
  29. Horsch A, Brechmayer D, Robert L, Horsch S. Antielastin antibodies in Buerger's disease. Verh Dtsch Ges Inn Med. 1977;83:1758
  30. Jacob MP, Hornebeck W, Lafuma C, et al. Ultrastructural and biochemical modifications of rabbit arteries induced by immunization with soluble elastin peptides. Exp Mol Pathol. 1984;41:171–190
  31. Wysokiński W. Peripheral necrosis of hind legs of rabbits immunized with elstin. Vasa. 1989;(Suppl. 27):73
  32. Evans MD, Pryor WA. Cigarette smoking, emphysema, and damage to alpha 1-proteinase inhibitor. Am J Physiol. 1994;266:L593–611
  33. Bergoeing MP, Arif B, Hackmann AE, et al. Cigarette smoking increases aortic dilatation without affecting matrix metalloproteinase-9 and -12 expression in a modified mouse model of aneurysm formation. J Vasc Surg. 2007;45:1217–1227
  34. Avcu F, Akar E, Demirkilic U, et al. The role of prothrombotic mutations in patients with Buerger's disease. Thromb Res. 2000;100:143–147
  35. Brodmann M, Renner W, Stark G, et al. Prothrombotic risk factors in patients with thrombangitis obliterans. Thromb Res. 2000;99:483–486
  36. Chen Z, Takahashi M, Naruse T, et al. Synergistic contribution of CD14 and HLA loci in the susceptibility to Buerger disease. Hum Genet. 2007;122:367–372
  37. Shionoya S. What is Buerger's disease?. World J Surg. 1983;7:544–551
  38. Papa MZ, Rabi I, Adar R. A point scoring system for the clinical diagnosis of Buerger's disease. Eur J Vasc Endovasc Surg. 1996;11:335–339
  39. Suzuki S, Mine H, Umehara I, Yoshida T, Okada Y. Buerger's disease (thromboangiitis obliterans): an analysis of the arteriograms of 119 cases. Clin Radiol. 1982;33:235–240
  40. Olin JW, Young JR, Graor RA, Ruschhaupt WF, Bartholomew JR. The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease). Circulation. 1990;82(5 Suppl):IV3–IV8
  41. Wysokiński WE, Kwiatkowska W, Masłowski L, Witkiewicz W, Kowal-Gierczak B. Buerger's disease in two brothers: iliac artery occlusion by thromboangiitis obliterans—case reports. Angiology. 1998;49:409–414
  42. Lie JT. Visceral intestinal Buerger's disease. Int J Cardiol. 1998;66(Suppl. 1):S249–S256
  43. No YJ, Lee EM, Lee DH, Kim JS. Cerebral angiographic findings in thromboangiitis obliterans. Neuroradiology. 2005;47:912–915
  44. Calguneri M, Ozturk MA, Ay H, et al. Buerger's disease with multisystem involvement. A case report and a review of the literature. Angiology. 2004;55(3):325–328
  45. Ohno H, Matsuda Y, Takashiba K, et al. Acute myocardial infarction in Buerger's disease. Am J Cardiol. 1986;57:690–691
  46. Donatelli F, Triggiani M, Nascimbene S, et al. Thromboangiitis obliterans of coronary and internal thoracic arteries in a young woman. J Thorac Cardiovasc Surg. 1997;113:800–802
  47. Goktas S, Bedir S, Bozlar U, Ilica AT, Seckin B. Intrarenal arterial stenosis in a patient with thromboangiitis obliterans. Int J Urol. 2006;13:1243–1244
  48. Puechal X, Fiessinger JN, Kahan A, Menkes CJ. Rheumatic manifestations in patients with thromboangiitis obliterans (Buerger's disease). J Rheumatol. 1999;26:1764–1768
  49. Borner C, Heidrich H. Long-term follow-up of thromboangiitis obliterans. Vasa. 1998;27:80–86
  50. Szuba A, Cooke JP. Thromboangiitis obliterans. An update on Buerger's disease. West J Med. 1998;168:255–260
  51. Cooper LT, Tse TS, Mikhail MA, et al. Long-term survival and amputation risk in thromboangiitis obliterans (Buerger's disease). J Am Coll Cardiol. 2004;44:2410–2411
  52. Szuba A, Wysokiński W, Czarnacki M, Kurzawska-Mielecka M. Coexistence of Buerger's disease with atherosclerosis obliterans. In: 9th International Symposium on Atherosclerosis. Rosemont, Illinois, USA, October 6–11. 1991;[Abstract; item 178]
  53. Fiessinger JN, Schafer M. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study. Lancet. 1990;335:555–557
  54. Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. The European TAO Study Group. Eur J Vasc Endovasc Surg 1998;15:300–7.
  55. Bozkurt AK, Koksal C, Demirbas MY, et al. A randomized trial of intravenous iloprost (a stable prostacyclin analogue) versus lumbar sympathectomy in the management of Buerger's disease. Int Angiol. 2006;25:162–168
  56. Two randomised and placebo-controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. The oral iloprost in severe Leg Ischaemia Study Group. Eur J Vasc Endovasc Surg 2000;20:358–62.
  57. Schuler JJ, Flanigan DP, Holcroft JW, et al. Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double-blind, multicenter clinical trial. J Vasc Surg. 1984;1:160–170
  58. Zdrojowy K, Adamiec R, Czarnacki M. New aspects of treatment with prostaglandin E1 in thrombangiitis obliterans. Pol Arch Med Wew. 2002;5:1071–1077
  59. Lazarides MK, Georgiadis GS, Papas TT, Nikolopoulos ES. Diagnostic criteria and treatment of Buerger's disease: a review. Int J Low Extrem Wounds. 2006;5:89–95
  60. Lau H, Cheng SW. Buerger's disease in Hong Kong: a review of 89 cases. Aust N Z J Surg. 1997;67:264–269
  61. Isner JM, Baumgartner I, Rauh G, et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg. 1998;28:964–973
  62. Swigris JJ, Olin JW, Mekhail NA. Implantable spinal cord stimulator to treat the ischemic manifestations of thromboangiitis obliterans (Buerger's disease). J Vasc Surg. 1999;29:928–935
  63. Talwar S, Jain S, Porwal R, Laddha BL, Prasad P. Free versus pedicled omental grafts for limb salvage in Buerger's disease. Aust N Z J Surg. 1998;68:38–40
  64. Saito Y, Sasaki K, Katsuda Y, et al. Effect of autologous bone-marrow cell transplantation on ischemic ulcer in patients with Buerger's disease. Circ J. 2007;71:1187–1192
  65. Wessler S, Ming SC, Gurewich V, Freiman DG. A critical evaluation of thromboangitis obliterans. The case against Buerger's disease. N Engl J Med. 1960;262:1149–1160
  66. Gore I, Burrows S. A reconsideration of the pathogenesis of Buerger's disease. Am J Clin Pathol. 1958;29:319–330
  67. Lindbom A. Arteriosclerosis and arterial thrombosis in the lower limb; a roentgenological study. Acta Radiol Suppl. 1950;80:1–80

PII: S0021-9150(09)00097-5

doi: 10.1016/j.atherosclerosis.2009.01.042

Atherosclerosis
Volume 206, Issue 2 , Pages 328-334 , October 2009

Article Tools

* Image Usage & Resolution